Published in Cancer Weekly, July 25th, 2000
The trial is designed to demonstrate whether treatment with Ramoplanin reduces the incidence of bloodstream infections due to Vancomycin-Resistant Enterococcus (VRE) in cancer patients known to carry VRE bacteria in their intestines.
The Ramoplanin trial is IntraBiotics' second Phase III clinical trial initiated this year. On May 4, 2000, the company announced it had begun a Phase III trial for its Protegrin IB-367 Oral Rinse, an antibiotic intended to reduce the severity of oral...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.